![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novartis Agrees to Purchase Cadent Therapeutics for Up to $770 Million
Novartis Agrees to Purchase Cadent Therapeutics for Up to $770 Million
December 21, 2020
Novartis has announced plans to purchase Cambridge, Mass.-based Cadent Therapeutics for up to $770 million, expanding its pipeline of treatments for cognitive and mood disorders.
Under the agreement, Novartis acquires two clinical-stage molecules for schizophrenia and movement disorders, and MIJ821, a clinical-stage molecule previously licensed exclusively by Novartis for treatment-resistant depression.
The Swiss pharmaceutical giant will pay $210 million upfront for Cadent, which will be eligible for payments of as much as $560 million upon meeting specific milestones. Cadent and Novartis expect to complete the transaction during the first quarter of 2021.
Upcoming Events
-
21Oct